- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06318195
Condensed Digital Prolonged Exposure for Individuals Treated Within Somatic Trauma Care. (CiPE)
Internet Delivered Condensed Cognitive Behavioral Treatment (Prolonged Exposure) for Individuals Treated Within Somatic Trauma Care.
Study Overview
Status
Intervention / Treatment
Detailed Description
The study is un-controlled with 250 participants that will undergo a brief trauma-focused Internet-based CBT treatment, delivered as a three-week treatment comprising of four modules (psychoeducation/rational, in vivo exposure, imaginal exposure and relapse prevention). The primary outcome is the PCL-5. Secondary outcomes are level of depression (PHQ-9), quality of life (WSAS) and predictors, moderators and mediators of clinically meaningful change in symptoms, dropout rate, rates of inclusion, attrition, adherence,and negative effects.
Self-reported, qualitative data from participants will be gathered at treatment completion to capture participants' experiences of participating in the intervention, as well as their views on how to further improve the intervention. The treatment effects will be evaluated using a within-group design with repeated measurements. Participants in the study will be will recruited from patients treated in the somatic trauma care at the Karolinska University Hospital in Stockholm, Sweden.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Maria Bragesjö, PhD
- Phone Number: +46703399387
- Email: maria.bragesjo@ki.se
Study Locations
-
-
-
Stockholm, Sweden
- Karolinska Universitetssjukhuset; Tema Kvinnohälsa och Hälsoprofessioner; Medicinsk Enhet Medicinsk Psykologi; Sektion Beteendemedicin
-
Contact:
- Charlotte Gentili, PhD
- Phone Number: +46760482895
- Email: charlotte.s.gentili@regionstockholm.se
-
Contact:
- Mike Kemani, PhD
- Email: mike.kemani@regionstockholm.se
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Exposed to trauma in the past two months according to criterion A for PTSD in the DSM-5 (exposed to death, threatened death, actual or threatened serious injury, or actual or threatened sexual violence).
- PCL-5 total sum score>10
- ≥ 18 years
- Situated in Sweden
- Signed informed consent
Exclusion Criteria:
- Other serious comorbidity as primary concern (ongoing substance dependence, untreated bipolar disorder, psychotic symptoms, severe depression, borderline personality disorder, high suicidal risk according to the MINI)
- Unable to read and write in Swedish
- Receiving other psychological trauma-focused treatment
- Ongoing trauma-related threat (e.g., living with a violent spouse)
- Not stable dose of antidepressant medication the last two weeks
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Condensed Internet delivered prolonged exposure (CIPE)
Condensed Internet delivered prolonged exposure (CIPE) for three weeks with therapist support.
|
Condensed Internet delivered prolonged exposure (CIPE) with therapist support for three weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in PTSD symptoms as assessed by the PTSD Check List - DSM-5 (PCL-5)
Time Frame: week -3, -2 and -1 before treatment start, immediately before start of treatment, weekly through three weeks of treatment, post-treatment (immediately after treatment completion at three weeks), and the 1 month and 6 months follow up.
|
The PCL-5 is a 20-item self-report measure based upon the Diagnostic and Statistical Manual (DSM-5) criteria for PTSD.
Total Score (Range 0-80 with higher scores representing more PTSD symptoms.
|
week -3, -2 and -1 before treatment start, immediately before start of treatment, weekly through three weeks of treatment, post-treatment (immediately after treatment completion at three weeks), and the 1 month and 6 months follow up.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in depressive symptoms as measured by the Patient Health Questionnaire-9 (PHQ-9)
Time Frame: week -3 before treatment start, immediately before start of treatment, weekly through three weeks of treatment, post-treatment (immediately after treatment completion at three weeks), and the 1 month and 6 months follow up.
|
The PHQ-9 is a widely used and well-validated instrument for measuring the severity of depressive symptoms.
Scores are calculated based on how frequently a person experiences 9 symptoms of depression ranging from "not at all" response is scored as 0; "several days" response is 1; "more than half the days" response is 2; and "nearly every day" response is 3. Higher scores represents more depressive symptoms.
|
week -3 before treatment start, immediately before start of treatment, weekly through three weeks of treatment, post-treatment (immediately after treatment completion at three weeks), and the 1 month and 6 months follow up.
|
|
Change in psychosocial impairment measured by The Work and Social Adjustment Scale (WSAS), adapted to symptoms of post-traumatic stress.
Time Frame: week -3 before treatment start, immediately before start of treatment, , weekly through three weeks of treatment, post-treatment (immediately after treatment completion at three weeks), and the 1 month and 6 months follow up.
|
WSAS is a short, self-reported instrument consisting of five items about psychosocial impairments rated on a nine-point Likert scale.
A higher score means more severe impairment.
|
week -3 before treatment start, immediately before start of treatment, , weekly through three weeks of treatment, post-treatment (immediately after treatment completion at three weeks), and the 1 month and 6 months follow up.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Participants satisfaction with treatment.
Time Frame: Immediately after treatment completion.
|
Qualitative questions pertaining participants satisfaction with the treatment.
|
Immediately after treatment completion.
|
|
Adverse events related to treatment.
Time Frame: Immediately after treatment completion.
|
Adverse events related to treatment measured by with a free text option where participant is instructed to describe the possible event in detail.
If the participant reported any adverse event, additional follow-up questions about intensity, duration etc. will also be given.
|
Immediately after treatment completion.
|
|
Number of completed treatment modules
Time Frame: Baseline up to 3 weeks
|
Data will be gathered on total number of completed modules during the three week treatment.
|
Baseline up to 3 weeks
|
|
Number of messages sent and received in the digital platform
Time Frame: Baseline up to 3 weeks
|
Data will be gathered on total number of messages sent and received in the digital platform during the three week treatment.
|
Baseline up to 3 weeks
|
|
Number of completed home work assignments by the participant during the treatment period
Time Frame: Baseline up to 3 weeks
|
Data will be gathered on total number of completed home work assignments by the participant during the three week treatment.
|
Baseline up to 3 weeks
|
|
The proportion of participants that conducts the weekly measures and further assessment points
Time Frame: Baseline up to 6 months
|
The proportion of participants that conducts the weekly measures and further assessment points
|
Baseline up to 6 months
|
|
The proportion of participants that go through the entire treatment period
Time Frame: Baseline up to three weeks
|
The proportion of participants that go through the entire treatment period
|
Baseline up to three weeks
|
|
Number of drop-outs from treatment
Time Frame: Baseline up to three weeks
|
Number of drop-outs from treatment
|
Baseline up to three weeks
|
|
Rates of inclusion to the study
Time Frame: Baseline
|
Data on rates of inclusion will be considered as an indication of the feasibility of the intervention.
|
Baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Maria Bragesjö, PhD, Karolinska Institutet
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023-06821-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.